Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Erstveröffentlichung

2021

Authors

DiNardo, Courtney D.

Schuh, Andre C.

Stein, Eytan M.

Montesinos, Pau

Wei, Andrew H.

et al.

Wissenschaftlicher Artikel

Published in

Lancet Oncology ; 22 (2021), 11. - S. 1597-1608. - ISSN 1470-2045. - eISSN 1474-5488

Link to publication

https://dx.doi.org/10.1016/S1470-2045(21)00494-0

Institutions

UKU. Klinik für Innere Medizin III

Subject headings

[Free subject headings]: INTERNATIONAL WORKING GROUP | ISOCITRATE DEHYDROGENASE 1 | RESPONSE CRITERIA | RECOMMENDATIONS | MUTATIONS | AML
[DDC subject group]: DDC 610 / Medicine & health

---

Metadata

Show full item record